Related content

Health Risk Assessment Practices in the U.S. Food and Drug Administration

By Gaylor D.W.   Axelrad J.A.   Brown R.P.   Cavagnaro J.A.   Cyr W.H.   Hulebak K.L.   Lorentzen R.J.   Miller M.A.   Mulligan L.T.   Schwetz B.A.  

Regulatory Toxicology and Pharmacology, Vol. 26, Iss. 3, 1997-12 ,pp. : 307-321

Academic Press

Access to resources Recommend Favorite

Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk

By  

Current Drug Abuse Reviews, Vol. 1, Iss. 2, 2008-06 ,pp. : 135-141

Bentham Science Publishers

Access to resources Recommend Favorite

The US Food and Drug Administration and Emergency Contraception

By Fox Anthony W.  

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 3, 2005-01 ,pp. : 139-140

Adis International

Access to resources Recommend Favorite

Pharmacogenomic considerations in drug delivery

By Attar Mayssa   Lee Vincent HL  

Pharmacogenomics, Vol. 4, Iss. 4, 2003-07 ,pp. : 443-461

Future Medicine

Access to resources Recommend Favorite

Consistency of drug–drug and gene–drug interaction information in US FDA-approved drug labels

By Conrado Daniela J   Rogers Hobart L   Zineh Issam   Pacanowski Michael A  

Pharmacogenomics, Vol. 14, Iss. 2, 2013-01 ,pp. : 215-223

Future Medicine

Access to resources Recommend Favorite